Paul B Manning

Director

Paul B Manning (Director) filed 3 Form 4 reports in the trailing twelve months (2 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Candel Therapeutics, Inc. (CADL). Across 2 priced purchase filings, the average 21-session return was +36.0% from execution and +33.7% from disclosure (delay-adjusted; derived). The largest single filing was $17.5M of VRCA (4,126,142 sh across 2 lots, as filed), executed Nov 25 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+36.0%

avg across 2 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+33.7%

same 2 filings, from disclosure

Filings, ttm

2 buys · 1 sells · 1 late

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$33.3M

shares × price, as filed

Last traded

Jun 4

Filed Jun 8

Median ADV $143.6M across their filed names

Impact on $10,000 · 12M

$16,315 (+63.2%)

S&P 500 $11,725 (+17.2%) · 45.9 pts ahead

Paul B Manning S&P 500

Compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $258.1M Sells $31.7M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names

CADL

Candel Therapeutics, Inc. CADL · 2 buys · 0 sells 2 filings LQDA Liquidia Corporation LQDA · 0 buys · 2 sells 2 filings VRCA VRCA VRCA · 2 buys · 0 sells 2 filings TSHA

Taysha Gene Therapies, Inc. TSHA · 1 buy · 0 sells 1 filing

Recent filings

LQDASALE Liquidia Corporation View filing → $12.8M
200,000 sh across 5 lots
Exec Jun 4
Filed Jun 8 · 5:30 PM ET CADLPURCHASE Candel Therapeutics, Inc. View filing → $3.0M
550,458 sh × $5.45
Exec Feb 23
Filed Feb 26 · 7:38 PM ET † VRCAPURCHASE Verrica Pharmaceuticals Inc. View filing → $17.5M
4,126,142 sh across 2 lots
Exec Nov 25 2025
Filed Nov 25 2025 · 7:00 PM ET LQDASALE Liquidia Corporation View filing → $19.0M
670,837 sh across 4 lots
Exec Aug 28 2025
Filed Sep 2 2025 · 5:30 PM ET TSHAPURCHASE Taysha Gene Therapies, Inc. View filing → $2.1M
750,000 sh × $2.75
Exec May 30 2025
Filed Jun 3 2025 · 5:30 PM ET CADLPURCHASE Candel Therapeutics, Inc. View filing → $7.5M
1,250,000 sh across 2 lots
Exec Dec 16 2024
Filed Dec 18 2024 · 5:30 PM ET VRCAPURCHASE Verrica Pharmaceuticals Inc. View filing → $228.1M
22,921,348 sh across 2 lots
Exec Nov 22 2024
Filed Nov 26 2024 · 5:30 PM ET LQDAPURCHASE Liquidia Corporation View filing → $3.0M
337,078 sh × $8.90
Exec Sep 12 2024
Filed Sep 16 2024 · 5:30 PM ET